Medivation Inc. (MDVN) almost doubled in early trading after saying that a trial of the company’s prostate cancer drug has been halted and the medicine will be given to all participants.
Medivation surged to $32 at 7:33 a.m. The trial’s monitoring committee made the recommendation after seeing interim results, the San Francisco-based company and partner Astellas Pharma Inc. (4503) said in a statement today.
To contact the reporter on this story: Bruce Rule in New York at email@example.com
To contact the editor responsible for this story: Bruce Rule at firstname.lastname@example.org